Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 11:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,354 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: moderate Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Mechanisms and Functional Outcomes of Exercise Progression Models in the Elderly

NCT01899586
View directory record Official record
Conditions
Elderly, Sedentary
Interventions
Regional Specific Training Stimulus (RSTS), Aerobic Exercise Regimen (AE)
Other
Lead sponsor
Duke University
Other
Eligibility
70 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Baton Rouge, Louisiana • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Sep 6, 2026, 11:03 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06589986
View directory record Official record
Conditions
Moderately to Severely Active Ulcerative Colitis
Interventions
Afimkibart, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
58
States / cities
Dothan, Alabama • Lancaster, California • Orange, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 6, 2026, 11:03 AM EDT
Completed Not applicable Interventional

Neurostimulation for Cognitive Enhancement in Alzheimer's Disease

NCT04404153
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver active tDCS., tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver sham tDCS.
Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 6, 2026, 11:03 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

NCT04134728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Sep 6, 2026, 11:03 AM EDT
Terminated Not applicable Interventional

Sonu Real-World Use Clinical Study to Treat Moderate to Severe Nasal Congestion

NCT06024564
View directory record Official record
Conditions
Nasal Congestion
Interventions
Sonu Acoustic Resonance Therapy
Device
Lead sponsor
Third Wave Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Sep 6, 2026, 11:03 AM EDT
Active, not recruiting Phase 3 Interventional

An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

NCT03950232
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrasimod
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years to 80 Years
Enrollment
896 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
132
States / cities
Dothan, Alabama • Lake Elsinore, California • Lancaster, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 6, 2026, 11:03 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

The Effectiveness of Regular Exercise on Improving Sleep in Older Adults

NCT00149747
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Sleep Disorders, Intrinsic
Interventions
Moderate-Intensity Aerobic Physical Activity, Health Education Class
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
55 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2003
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Sep 6, 2026, 11:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function

NCT04209049
View directory record Official record
Conditions
Overweight, Obesity
Interventions
NNC0174-0833
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Sep 6, 2026, 11:03 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Philips AirFlosser Study

NCT01700348
View directory record Official record
Conditions
Gingivitis
Interventions
Airflosser, Manual Floss
Device
Lead sponsor
Tufts University
Other
Eligibility
18 Years to 70 Years
Enrollment
257 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Sep 6, 2026, 11:03 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Step-up to Quit: Using Low-to-moderate Intensity Exercise for Reducing Smoking Cue Reactivity Among Low-income Smokers

NCT02220465
View directory record Official record
Conditions
Sedentary Lifestyle, Cigarette Smoking
Interventions
PA+ Smoking Cessation (LMPA), Standard Care Smoking Counseling (SCC)
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years to 59 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Sep 6, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia

NCT00405067
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
BMS-201038 (AEGR-733), Ezetimibe
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Sep 6, 2026, 11:03 AM EDT
Completed Not applicable Interventional Results available

Feasibility Testing of Patient Reported Outcomes - Informed Symptom Management System (PRISMS)

NCT04492007
View directory record Official record
Conditions
Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Cervical Cancer, Uterine Cancer
Interventions
Patient-Reported Outcomes-Informed Symptom Management System (PRISMS)
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 6, 2026, 11:03 AM EDT
Completed Phase 4 Interventional

Changes to Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Prasterone in Women With Dyspareunia

NCT03568604
View directory record Official record
Conditions
Dyspareunia
Interventions
Prasterone
Drug
Lead sponsor
San Diego Sexual Medicine
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 6, 2026, 11:03 AM EDT
Completed Phase 4 Interventional

Risankizumab Long-term Remission Study

NCT04630652
View directory record Official record
Conditions
Psoriasis
Interventions
Risankizumab-Rzaa, Punch biopsies of the skin at baseline visit, Punch biopsies of the skin at week 28 visit
Drug · Procedure
Lead sponsor
Jaehwan Kim
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Sacramento, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 6, 2026, 11:03 AM EDT
Recruiting Not applicable Interventional

Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease

NCT06088355
View directory record Official record
Conditions
Parkinson Disease, Movement Disorders, Neurodegeneration
Interventions
HV-PDAE: High Volume Partnered Dance Aerobic Exercise, MV-PDAE: Moderate Volume Partnered Dance Aerobic Exercise, MV-WALK: Moderate Volume Walking, HV-WALK: High Volume Walking
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 6, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor

NCT00598078
View directory record Official record
Conditions
Essential Tremor
Interventions
Sodium Oxybate, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
50 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Bingham Farms, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 22, 2012 · Synced Sep 6, 2026, 11:03 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Determinants of Changes in Arterial Load Following Exercise

NCT05820243
View directory record Official record
Conditions
Post-Exercise Hypotension
Interventions
Moderate Intensity Aerobic Exercise
Other
Lead sponsor
University of Delaware
Other
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 6, 2026, 11:03 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment

NCT04292730
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
Enrollment
1,113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
106
States / cities
Anaheim, California • Berkeley, California • Burlingame, California + 76 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Sep 6, 2026, 11:03 AM EDT
Completed Phase 3 Interventional Results available

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

NCT02873936
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib, csDMARDs
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
55
States / cities
Huntsville, Alabama • Gilbert, Arizona • Covina, California + 52 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 6, 2026, 11:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

NCT00964821
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions
trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Sep 6, 2026, 11:03 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis

NCT03589885
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Placebo 2 mL auto-injector, Placebo 1 mL prefilled syringe, Secukinumab 2 mL auto-injector, Secukinumab 1 mL prefilled syringe
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
8
States / cities
Miami, Florida • Marietta, Georgia • Saint Joseph, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 6, 2026, 11:03 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT06979336
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
RO7837195, RO7837195 Matched Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Lancaster, California • San Diego, California • Colorado Springs, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 6, 2026, 11:03 AM EDT
Terminated Not applicable Interventional Results available

CeraVe Cream Compared to Desitin Paste for Treating Diaper Dermatitis in Infants

NCT02299206
View directory record Official record
Conditions
Diaper Rash
Interventions
CeraVe Baby Diaper Rash Cream, Desitin Maximum Strength Original Paste
Drug
Lead sponsor
Northwestern University
Other
Eligibility
3 Months to 18 Months
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 6, 2026, 11:03 AM EDT
Completed Phase 3 Interventional

The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease

NCT00090116
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Neramexane
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
34
States / cities
Peoria, Arizona • Phoenix, Arizona • Fresno, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2012 · Synced Sep 6, 2026, 11:03 AM EDT